DARBEPOETIN ALFA — all Canadian products
24 DINs
19 marketed/approved
0 in shortage
Every Health Canada Drug Identification Number whose active ingredient is DARBEPOETIN ALFA, with holder, form, strength and current status, compared weekly against the Drug Product Database.
| DIN | Product | Company | Form | Route | Strength | Status | Shortage |
|---|---|---|---|---|---|---|---|
| 02392356 | ARANESP | AMGEN CANADA INC | Solution | Intravenous; Subcutaneous | DARBEPOETIN ALFA 200 MCG | Marketed | |
| 02246353 | ARANESP | AMGEN CANADA INC | Solution | Intravenous; Subcutaneous | DARBEPOETIN ALFA 15 MCG | Approved | |
| 02392313 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 25 MCG | Marketed | |
| 02392321 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 40 MCG | Marketed | |
| 02392348 | ARANESP | AMGEN CANADA INC | Solution | Intravenous; Subcutaneous | DARBEPOETIN ALFA 100 MCG | Marketed | |
| 02392364 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 500 MCG | Marketed | |
| 02246359 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 325 MCG | Approved | |
| 02246356 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 60 MCG | Approved | |
| 02391732 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 40 MCG | Approved | |
| 02391740 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 100 MCG | Marketed | |
| 02391759 | ARANESP | AMGEN CANADA INC | Solution | Intravenous; Subcutaneous | DARBEPOETIN ALFA 100 MCG | Marketed | |
| 02391767 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 200 MCG | Marketed | |
| 02391775 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 200 MCG | Marketed | |
| 02391783 | ARANESP | AMGEN CANADA INC | Solution | Intravenous; Subcutaneous | DARBEPOETIN ALFA 200 MCG | Marketed | |
| 02391791 | ARANESP | AMGEN CANADA INC | Solution | Intravenous; Subcutaneous | DARBEPOETIN ALFA 500 MCG | Marketed | |
| 02391805 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 500 MCG | Marketed | |
| 02391813 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 500 MCG | Approved | |
| 02391821 | ARANESP | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 500 MCG | Marketed | |
| 02391848 | ARANESP | AMGEN CANADA INC | Solution | Intravenous; Subcutaneous | DARBEPOETIN ALFA 500 MCG | Approved | |
| 02246354 | ARANESP | AMGEN CANADA INC | Solution | Intravenous; Subcutaneous | DARBEPOETIN ALFA 25 MCG | Cancelled Post Market | |
| 02246355 | ARANESP -(HSA-FREE) | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 40 MCG | Cancelled Post Market | |
| 02246360 | ARANESP -(HSA-FREE) | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 500 MCG | Cancelled Post Market | |
| 02246357 | ARANESP -(HSA-FREE) | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 100 MCG | Cancelled Post Market | |
| 02246358 | ARANESP -(HSA-FREE) | AMGEN CANADA INC | Solution | Subcutaneous; Intravenous | DARBEPOETIN ALFA 200 MCG | Cancelled Post Market |
Browse other molecules: